ArcherDX target enrichment kits for NGS detect all major types of oncogenic MET aberrations

By Laura Griffin, PhD on Wed Feb 10, 2016


  • Deregulation of the receptor tyrosine kinase, MET, is implicated in a variety of human cancers, promoting proliferation, invasive growth and angiogenesis.
  • MET deregulation can be driven by upregulation of MET transcription as well as several types of genetic aberrations, including:
    • Gene fusions
    • Activating point mutations
    • METex14 isoform expression (exon 14 skipping)
    • Gene amplification
  • ArcherDX, Inc. provides target enrichment kits for NGS library preparation and a downstream NGS analysis platform that can be used to detect each of these types of MET alterations (Table 1).

Biological functions of MET

Mesenchymal-epithelial transition factor (MET) is a proto-oncogene located on chromosome 7 that encodes a receptor tyrosine kinase expressed on the surface of epithelial cells (1, 2). Activation by extracellular hepatocyte growth factor (HGF) binding induces dimerization and autophosphorylation of MET’s cytoplasmic kinase domain and subsequent activation of downstream pathways that regulate cell survival, motility and proliferation (3-6)(reviewed in (7)) (Figure 1). MET aberrations resulting in constitutive or prolonged activation confer an aggressive phenotype in cancer, promoting tumor proliferation, invasive growth and angiogenesis (reviewed in (7, 8)). Originally identified in papillary renal cell carcinoma (PRC), MET aberrations have now been implicated in a variety of neoplasms, including non-small cell lung cancer (NSCLC), gastric adenocarcinoma and pancreatic, esophageal, thyroid, colorectal, ovarian and breast cancers (9-11). Furthermore, aberrant MET activation often confers acquired resistance to EGFR inhibitors in EGFR-driven cancers, primarily due to cross-talk between these two tyrosine kinase signaling pathways (12-15). MET activation can be inhibited in multiple ways: 1) inhibition of HGF maturation which prevents HGF ligand binding and subsequent MET activation; 2) small molecule or antibody-mediated neutralization of HGF-MET binding; and 3) intracellular inhibition of MET kinase activity by both selective and nonselective tyrosine kinase inhibitors (reviewed in (11, 16)).

HGF ligand binding induces dimerization, autophosphorylation and activation of MET, which further induces several pathways that promote cell survival, proliferation and motility.
Figure 1. HGF ligand binding induces dimerization, autophosphorylation and activation of MET.

Causes of MET deregulation

Constitutive or prolonged MET activation and subsequent tumorigenesis can result from genetic MET alterations, MET overexpression or aberrant HGF-dependent autocrine/paracrine signaling (reviewed in (17)). Genetic alterations of MET include gene fusions, kinase-activating point mutations, mutations that drive the production of an isoform lacking exon 14 (aka “exon 14 skipping”) and gene amplifications. Detecting these genetic alterations as well as the expression level of MET is necessary to identify the underlying cause of MET deregulation, which dictates which inhibitors effectively block MET activation. As detailed below, the Archer™ VariantPlex™ and FusionPlex™ assays can detect all known types of MET aberrations and can therefore be used to determine the cause of MET deregulation.

MET gene fusions

Since the original in vitro characterization of the oncogenic TPR-MET fusion in human osteogenic sarcoma cells, several MET fusions have been identified in an array of human cancers, including low-grade glioma, hepatocellular carcinoma, lung adenocarcinoma, thyroid carcinoma and PRC (18, 19). As a shared mechanism, MET fusion proteins lack a transmembrane domain as well as the portion of the protein that is normally targeted for ubiquitin-mediated degradation (Figure 2). Furthermore, the fusion partner contains a dimerization motif that induces ligand-independent dimerization and thus autophosphorylation and constitutive activation of the MET kinase domain. Therefore, MET fusion proteins are constitutively active, intracellular proteins with prolonged stability. These intracellular fusion proteins are inaccessible to inhibitors of HGF ligand binding, thereby limiting MET inhibition to intracellular kinase inhibitors. MET fusions can be detected using the following Archer FusionPlex kits:

MET fusion proteins are intracellular and exhibit prolonged stability and constitutive activation, promoting proliferation, invasive growth and angiogenesis leading to tumorigenesis.
Figure 2. MET fusion proteins are intracellular and exhibit prolonged stability and constitutive activation.

Kinase-activating point mutations in MET

Activating point mutations in the tyrosine kinase domain of MET were originally discovered in hereditary papillary renal carcinoma (PRC) and somatic activating mutations have since been identified in a subset of sporadic PRC, NSCLC, gastric, head and neck, liver, ovarian, thyroid carcinomas (reviewed in (20)). Data obtained from hereditary PRC tumors indicate that multiple copies of the mutated MET gene are necessary to confer an oncogenic phenotype, as trisomy of chromosome 7 accompanies heterozygous MET mutations in this disease (9). Importantly, mutations occurring in the kinase domain can alter the sensitivity of MET to kinase inhibitors (21). The Archer VariantPlex CTL and Solid Tumor assays cover hot spots in the kinase domain of MET, thus detecting activating point mutations in MET.

Exon 14 skipping (METex14)

METex14, an isoform of MET which lacks exon 14, is an important driver of tumorigenesis in lung adenocarcinoma, other lung neoplasms and brain glioma (22-25). Similar to MET fusion proteins described above, METex14 proteins exhibit prolonged stability due to the loss of their ubiquitin-binding domain, which is encoded by exon 14 (Figure 3). This increased stability of METex14 membrane-bound proteins results in increased HGF/MET-dependent signaling, thereby promoting tumorigenesis. Importantly, a recent study by G.M. Frampton and colleagues demonstrated that MET sequence variants driving exon 14 skipping are highly diverse, with 126 distinct sequence variants detected in 221 cases of METex14 expression (22). More than half of these variants were insertions and deletions (indels) of varying sizes and the rest were base substitutions most frequently occurring in the vicinity of splice acceptor and splice donor sites. As MET mRNA sequence information can be used to detect exon skipping regardless of underlying genomic alterations, RNA-seq (mRNA sequencing) is invaluable in detecting METex14. The aforementioned Archer FusionPlex assays can detect exon 14 skipping leading to expression of the METex14 isoform. MET DNA sequence variants can also be detected by Archer VariantPlex Solid Tumor and Archer VariantPlex CTL assays. MET mRNA and DNA sequence information obtained using these kits provides a means to detect METex14 as well as identify underlying driver mutations.

METex14, an isoform resulting from exon 14 skipping, is a splice variant that exhibits prolonged stability and HGF ligand-dependent activation on the cell surface, resulting in induced proliferation, invasive growth and angiogenesis and thereby promoting tumorigenesis.
Figure 3. METex14, an isoform resulting from exon 14 skipping, exhibits prolonged stability and ligand-dependent activation on the cell surface.

MET gene amplifications

MET gene amplifications have been detected in a variety of cancers, yet perhaps the most interesting finding is that these amplifications have been observed in liver metastases from colon carcinoma and in cancers with acquired EGFR drug-resistance (13, 15, 26). This indicates that MET amplifications can arise throughout the course of tumor progression, conferring a more aggressive phenotype. MET amplifications result in increased protein expression levels and subsequent increased MET-dependent signaling. MET amplifications can be detected by the VariantPlex Solid Tumor and VariantPlex CTL assays and the resulting increased expression levels of MET mRNA can be detected by the FusionPlex CTL assay.

Transcriptional upregulation of MET

Transcriptional upregulation of MET is the most frequent cause of constitutive MET activation in human tumors and has been implicated in thyroid, colorectal, ovarian, pancreatic, lung and breast carcinomas (27). Genetic alterations frequently found in cancers, such as RAS mutations and TP53 loss-of-function, result in activation of MET transcription (28). However, one of the most common causes of transcriptional upregulation is hypoxia, which often occurs at the center of a rapidly growing tumor (29). Hypoxia-inducible factor 1α (HIF1α), a transcription factor of MET, induces MET transcription in response to decreases in intracellular oxygen levels (30). As with MET gene amplifications, transcriptional upregulation of MET results in increased levels of surface-bound MET and ligand-dependent MET signaling. In both cases, the FusionPlex CTL kit can be used to determine relative expression levels of MET. Furthermore, the VariantPlex CTL or VariantPlex Solid Tumor kit in conjunction with the expression data obtained by the FusionPlex CTL kit can be used to distinguish between overexpression caused by gene amplification versus transcriptional upregulation.


Activation of the MET receptor tyrosine kinase is deregulated in an array of human cancers of epithelial origin (10, 11). Constitutive or prolonged MET activation leads to the induction of several signaling pathways that promote tumorigenesis (7). Aside from dysregulated ligand-dependent autocrine and paracrine signaling, several types of genomic aberrations have been identified that drive MET deregulation, including gene fusions, activating point mutations, expression of the isoform METex14 and gene amplification (17). Transcriptional upregulation, which typically occurs in response to the unique tumor microenvironment, also leads to constitutive MET activation and subsequent promotion of tumorigenesis. ArcherDX provides VariantPlex and FusionPlex kits that enable detection of all known types of genetic lesions leading to MET deregulation as well as determine relative mRNA expression levels. Please see Table 1 below for a summary of known MET alterations, their downstream effect on MET proteins and the Archer kits that can be used to detect them.

Table 1. List of known MET alterations and the Archer kits that can be used to detect them.
Aberration type Result of aberration FusionPlex Kit VariantPlex Kit
Gene fusion
  • Intracellular
  • Constitutive activation
  • Prolonged stability
Activating point mutation Constitutive activation N/A
Exon 14 skipping (METex14) Prolonged stability N/A
Gene amplification Increased protein level CTL
Transcriptional upregulation Increased protein level CTL N/A


  1. C. CS et al., Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 311, 29–33 (1983).
  2. S. Giordano, C. Ponzetto, M. F. Di Renzo, C. S. Cooper, P. M. Comoglio, Tyrosine kinase receptor indistinguishable from the c-met protein. Nature. 339, 155–156 (1989).
  3. L. Naldini et al., Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene. 6, 501–504 (1991).
  4. D. P. Bottaro et al., Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 251, 802–804 (1991).
  5. G. A. Rodrigues, M. Park, in Tyrosine Phosphorylation/Dephosphorylation and Downstream Signalling (Springer Berlin Heidelberg, Berlin, Heidelberg, 1993), pp. 103–106.
  6. C. Ponzetto et al., A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 77, 261–271 (1994).
  7. L. Trusolino, A. Bertotti, P. M. Comoglio, MET signalling: principles and functions in development, organ regeneration and cancer. Nature Reviews Molecular Cell Biology. 11, 834–848 (2010).
  8. A. Gentile, L. Trusolino, P. M. Comoglio, The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27, 85–94 (2008).
  9. L. Schmidt et al., Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics. 16, 68–73 (1997).
  10. E. Gherardi, W. Birchmeier, C. Birchmeier, G. V. Woude, Targeting MET in cancer: rationale and progress. Nature Reviews Cancer. 12, 89–103 (2012).
  11. E. Smyth, F. Sclafani, D. Cunningham, Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. OTT. 7, 1001–1014 (2014).
  12. A. Bardelli et al., Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discovery. 3, 658–673 (2013).
  13. J. A. Engelman et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316, 1039–1043 (2007).
  14. E. Benedettini et al., Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol. 177, 415–423 (2010).
  15. J. Bean et al., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. PNAS. 104, 20932–20937 (2007).
  16. Y. Zhang, R. Jain, M. Zhu, Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. Biomedicines. 3, 149–181 (2015).
  17. S. L. Organ, M. S. Tsao, An overview of the c-MET signaling pathway. Therapeutic Advances in Medical Oncology. 3, S7–S19 (2011).
  18. M. Park et al., Mechanism of met oncogene activation. Cell. 45, 895–904 (1986).
  19. N. Stransky, E. Cerami, S. Schalm, J. L. Kim, C. Lengauer, The landscape of kinase fusions in cancer. Nature Communications. 5, 4846 (2014).
  20. M. Zenali et al., Retrospective Review of MET Gene Mutations. Oncoscience. 2, 533–541 (2015).
  21. S. Berthou et al., The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene. 23, 5387–5393 (2004).
  22. G. M. Frampton et al., Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discovery. 5, 850–859 (2015).
  23. P. C. Ma et al., c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63, 6272–6281 (2003).
  24. P. C. Ma et al., Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479–1488 (2005).
  25. M. Kong-Beltran et al., Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66, 283–289 (2006).
  26. M. F. Di Renzo, R. Poulsom, M. Olivero, P. M. Comoglio, N. R. Lemoine, Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 55, 1129–1138 (1995).
  27. P. M. Comoglio, S. Giordano, L. Trusolino, Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 7, 504–516 (2008).
  28. M. Ivan, J. A. Bond, M. Prat, P. M. Comoglio, D. Wynford-Thomas, Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene. 14, 2417–2423 (1997).
  29. S. Pennacchietti et al., Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 3, 347–361 (2003).
  30. Y. Kitajima, T. Ide, T. Ohtsuka, K. Miyazaki, Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 99, 1341–1347 (2008).

About Laura Griffin, PhD

Laura Griffin earned her PhD in Microbiology from the University of Colorado Denver, Anschutz Medical Campus. Her research focused on cancer virology, dissecting virus-host interactions during Human Papillomavirus infection. Laura is passionate about cancer research as well as effective education and communication of scientific ideas. Laura joined the ArcherDX team as Scientific Editor in January, 2016. In her spare time, Laura is a group fitness instructor and enjoys cycling, hiking, skiing, and snowshoeing in the Rocky Mountains of Colorado.

How to contact us


2477 55th Street, Suite 202

Boulder, CO 80301


Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2019 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.